Targeting IgA Nephropathy (Sponsored Content)

Rachel Benton is a loving mother to an adorable 2-year-old boy named Stetson. Stetson doesn’t know it, but he may have already saved his mom’s life. A routine medical checkup, that Rachel only had because she was pregnant, showed protein in her urine. That discovery led to a biopsy and ultimately a diagnosis of IgA nephropathy – a serious kidney disease. With patients like Rachel in mind, the research team at Vertex Pharmaceuticals is working on new approaches to address IgA nephropathy. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. See omnystudio.com/listener https://omnystudio.com/listener for privacy information.

• 0:00Speaker 00

  Since you're a subscriber to this Bloomberg podcast, we thought you'd be interested in a six-episode sponsored podcast called "Targeting the Toughest Diseases", produced by Vertex Pharmaceuticals and Bloomberg Media Studios. It explores the innovative tools, methods, and unique philosophy Vertex Pharmaceuticals is using to search for treatments for some of humanity's most challenging diseases. Here's a recent episode.

• 0:30Speaker 01

  Two-year-olds are a handful. They're full of energy and full of laughter. A lot of work, for sure, but also a source of joy.

• 0:43Speaker 02

  I definitely feel my calling in life was to be a mother and I just feel so blessed to be able to have that opportunity to have a child. So it's been great.

• 0:56Speaker 01

  That's Rachel Benton, also known as Stetson's mom.

• 1:00Speaker 02

  Stetson is his name, Stetson Cory Benton. I've always liked unique names. I never knew of anyone named Stetson before.

• 1:11Speaker 01

  The thing about Stetson is, and he doesn't even know this yet, but he may have already saved his mom's life.

• 1:20Speaker 01

  A routine medical test that Rachel only took because she was pregnant showed protein in her urine. That led to further tests, a biopsy, and eventually a phone call delivering a diagnosis.

• 1:35Speaker 02

  It was a pretty quick conversation. We know it is IgA nephropathy. It's a rare kidney disease. There is not a cure. We don't have a cause.

• 1:46Speaker 01

  The call was short, but for Rachel, it changed everything.

• 1:56Speaker 01

  Hi, I'm Jordan Gaspore, a member of the University of Southern California's Center for Health Journalism. This is Targeting the Toughest Diseases, a podcast produced by Bloomberg Media Studios and Vertex Pharmaceuticals. In this series, we look at some of humanity's most challenging diseases and how Vertex, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Today, we're looking at immunoglobulin A nephropathy, more commonly known as IgA nephropathy. It's a progressive chronic kidney disease that, for too long, was underreported and

• 2:40Speaker 01

  under-researched. We'll talk to experts inside and outside of Vertex about the latest work being done in this field. But first, back to Rachel's story.

• 2:58Speaker 01

  At the age of 30, Rachel Benton was living a great life. She was a licensed mortgage broker, running her own agency. She owned her own house, and that fall, she decided to throw a big Halloween party.

• 3:12Speaker 02

  And he came with one of our mutual friends, and we sort of rekindled from there.

• 3:18Speaker 01

  He was Tom, a guy she had dated on and off during her 20s.

• 3:23Speaker 02

  And then it was the end of November of 2020 that he asked me to marry him.

• 3:29Speaker 01

  A year later, they got married, and shortly after that, Rachel got pregnant. During her pregnancy, Rachel had regular medical checkups, including routine urine tests.

• 3:42Speaker 02

  We did a urine test, a 24-hour urine test, and that's where you have to take this big jug home, and you have to pee straight into this jug every time for 24 hours. And so I bring it to the doctor, and they test it, and sure enough, they found protein in my urine.

• 4:01Speaker 01

  The doctor told her she wasn't facing any immediate risk, so they agreed to put that result aside, focus on having a healthy baby, and that they would investigate further once the baby was born.

• 4:14Speaker 01

  Stetson Corey Benton was born in May, and as a new parent, Rachel's life instantly became a whirlwind.

• 4:21Speaker 02

  Honestly, I completely even forgot about the kidney stuff.

• 4:25Speaker 01

  But around the nine-month mark, she reached out to her doctor. She retested her urine, which confirmed she still had protein in her urine. So they decided to do a kidney biopsy. A biopsy is where a doctor uses a long needle to extract tiny pieces of tissue so they can do further tests. Rachel got the results over the phone.

• 4:49Speaker 02

  And he's like, you know, we did confirm some things. You have a rare kidney disease called IgA nephropathy or IgAN. So my first question was, you know, what do I do now? How do I stop this? Is there a cure? You know, just thinking of anything like, what's the next steps? What about medication, blah, blah, blah? And he's like, well...

• 5:13Speaker 01

  The answer to almost all of her questions was, "We're not sure," or "It depends."

• 5:21Speaker 02

  I got off the phone and just cried, I think, for probably two days straight.

• 5:29Speaker 02

  I just was overwhelmed with, obviously, the diagnosis and not knowing where this would take me in life, what the next, you know, 24 hours would look like, a year, 10 years, you know? How is this going to affect me in my day-to-day life? And my son and my husband?

• 5:51Speaker 01

  She's adjusted her diet and takes medication to address her blood pressure and cholesterol. But the progress of the disease is variable.

• 6:01Speaker 01

  At one point, Rachel's kidney function dropped 30 points over two months. The doctor told her that, at that rate, she'd be needing dialysis within a year. She's rebounded, but she doesn't know if that recovery will hold.

• 6:18Speaker 01

  She also deals with fatigue. Not just new mom tiredness, but debilitating fatigue, where she'll sleep for 12 hours and still need a midday nap. In fact, Rachel says that for a couple of years before her diagnosis, she was already dealing with extreme tiredness, but never really considered it a medical condition or something that needed attention. In hindsight, she wishes she had gotten it checked out. Looking forward, her long-term health and her ability to be the kind of mom she wants to be is uncertain.

• 6:54Speaker 02

  I have my days where I just feel very, very guilty being a mother to him with a rare disease and not knowing in a year or 10 years, however long, how I'm going to be and how active I get to be in his life. Every day, I just try to make the best of it, though. And, you know, whatever he wants to do, I put on a smile and try to push through.

• 7:22Speaker 01

  Immunoglobulin A nephropathy, or IGAN, is not a high-profile disease. It's a chronic kidney disease that, historically, has not been well-understood. But that's changing.

• 7:35Speaker 03

  So I do clinicals, so I see patients with glomerulone disease. I run clinical trials, and I have my research work at the university in the laboratory.

• 7:46Speaker 01

  That's Dr. Jonathan Barrett. He's based at the University of Leicester in England and is a world-renowned leader in kidney research.

• 7:54Speaker 03

  So most of my career, no one was really interested in IGAN nephropathy, apart from a few people. Now it is, you can't move at a kidney meeting without people talking about IGAN nephropathy.

• 8:05Speaker 01

  One reason it was so under-researched is that in the early stages, symptoms are often hard to detect.

• 8:11Speaker 03

  Normally, the patients I see have no idea why they're coming to see a kidney doctor.

• 8:16Speaker 01

  In many cases, it starts with an asymptomatic person having a urine test, like in Rachel's case, with a routine urine test during pregnancy.

• 8:25Speaker 03

  Perhaps you've joined a new gym. You get a physical. She wants to get a mortgage. You might have a job that requires you to have a physical. And someone dips your urine, and they say, "Oh, wait a minute. There's blood and protein in here."

• 8:37Speaker 01

  Here's what we do know about the disease.

• 8:40Speaker 03

  So each kidney contains about a million filters, and they are continually filtering the blood to generate the urine. And in IgA nephropathy, this protein called IgA starts sludging up those filters and stopping them from working properly. And if the filters don't work very well, they become leaky, and blood and protein can appear in the urine.

• 9:03Speaker 01

  Over time, sometimes months, sometimes years, your kidney function declines.

• 9:10Speaker 03

  Some patients do really well with IgA nephropathy, and others end up on dialysis relatively quickly. And that's the bit we haven't quite worked out yet.

• 9:18Speaker 01

  In fact, we know the majority of adult patients with IgA nephropathy will progress to end-stage kidney disease, which requires them to go on dialysis or get a transplant within 20 years of diagnosis. Dr. Barrett says there is evidence of a genetic component, but the connections aren't strong enough to do genetic screening. Right now, the only way to diagnose IgA nephropathy is with a kidney biopsy.

• 9:45Speaker 03

  But what we think is the major driver for this disease is the type of IgA we normally produce in our gut and in our respiratory tract that normally gets into our sputum, into our tears, into our saliva. It's there to stop bugs entering the body, and it does a very, very good job. But in IgA nephropathy, some of that IgA actually gets into the bloodstream. But when it's in the bloodstream, it's a bit out of place, and it tends to stick to itself, to stick to other proteins. There are antibodies in the circulation it sticks to, and that forms these large, what we call immune complexes, which are essentially big aggregates of protein.

• 10:24Speaker 03

  If you've got big globs of protein, it's completely reasonable to think that those globs of protein are going to start clogging up the filter, which is exactly what happens. And when they clog up the filter, there's inflammation, there's scarring, and that's what eventually causes kidney failure.

• 10:39Speaker 01

  For people diagnosed with IgA nephropathy, the biological effects are only part of the problem.

• 10:45Speaker 03

  The big challenge is actually the impact on mental wellness. Because if you're a young person, and I tell you you've got this disease... It's incurable. There's a risk it could cause kidney failure in the future, but I can't tell you when. You might need to go on dialysis or have a kidney transplant, but I can't tell you when. That sense of uncertainty can be absolutely devastating for young people. You imagine developing your career, wanting to pay that big amount of money for a house, getting married, thinking about children. And you have this threat hanging over you of a disease that the doctors can't really predict.

• 11:25Speaker 01

  Addressing that fear and uncertainty requires showing patients there is a way forward. And that's what the team at Vertex is doing.

• 11:35Speaker 01

  IgA nephropathy represents exactly the kind of medical problem Vertex is targeting. There's a long history of research to build on. There's new technology available, or Vertex thinks they can develop it. There's a large unmet need, and Vertex thinks it may be possible to tackle the underlying disease.

• 11:55Speaker 04

  Simply put, Vertex's goal is to help people suffering from serious diseases. And we do that by investing in scientific innovation to create what we believe could be truly transformative medicines for people with these diseases.

• 12:07Speaker 01

  That's Mark Bunnage. He's the head of research at Vertex Pharmaceuticals and leads research on the company's pipeline of serious diseases.

• 12:16Speaker 04

  Now, we focus on causal human biology and on human-validated targets. And then we ask the question, what's the right approach to take? And we are completely methodology agnostic. We'll use whatever is the right tool in the toolbox, if you like, to address their biology and then to come up with a transformative therapy.

• 12:37Speaker 01

  Earlier, Dr. Barrett explained how IgA nephropathy occurs. It's a buildup of what he calls "big globs of protein" that deposit and cause injury to the filters in your kidneys.

• 12:50Speaker 01

  But how can we stop that from happening? To answer that, I sat down with Dr. Manish Maskey. He's a board-certified nephrologist, helping lead Vertex's research into IgA nephropathy. Dr. Maskey explained that B-cells, an important part of our immune system to fight off infections, can lose control and produce antibodies that hurt our own organs. In this case, the kidneys.

• 13:17Speaker 01

  Can you tell us a little bit about where the field is going and what's being done for people living with IgA nephropathy?

• 13:23Speaker 05

  Absolutely. We now understand that loss of B-cell control is what leads to the downstream mechanisms resulting in kidney injury and kidney function loss. So lots of research has been performed to try to understand what is influencing the B-cell to lose control. It turns out that two proteins called BAF and APRIL are key drivers.

• 13:53Speaker 01

  Okay, so B-cells are a type of white blood cell that helps power our immune system. Can you tell us a little bit more about what BAF and APRIL are and how they're involved in B-cell control and how all of that relates to IgA nephropathy?

• 14:11Speaker 05

  So first, Jordan, you're absolutely right that B-cells, when they're doing what they're supposed to do, protect us from infections. They make antibodies that help us neutralize various pathogens. When B-cells lose control, they can set off a cascade of events that result in processes that harm the body, so-called autoimmune diseases. BAF and APRIL are two similar but distinct proteins that control the life cycle of the B-cell. So BAF more in the early stage of development and maturation of the B-cell and APRIL more

• 14:55Speaker 05

  in the later stage of the B-cell development, all the way through to it becoming an antibody-secreting cell. BAF and APRIL really seem to be two of the most critical proteins driving this transition from something that would protect us to something that would actually make antibodies that will harm our native tissues.

• 15:21Speaker 01

  This is a complex scenario. What's the innovative thinking that Vertex is considering here?

• 15:27Speaker 05

  We know that the levels of BATH and APRIL are actually elevated in people with IgA nephropathy, and that these levels correlate with measures of kidney function and damage. So through that, we believe both of these drivers are involved in uncontrolled B cells, not BATH alone and not APRIL alone. There's a need to cast the widest net to catch the main actors involved in the pathogenesis of IgA nephropathy. What we hope to see with this approach is the potential to restore immune balance for our patients and give them the best chance at remission in the proteinuria, which is the protein spilling in the urine, hematuria, which is the spilling of blood in the urine,

• 16:11Speaker 05

  with associated stabilization of kidney function.

• 16:16Speaker 01

  For Rachel Benton, living with uncertainty has become a constant burden.

• 16:23Speaker 02

  It really scares me for my son. I feel like I let him down, I guess. You know, it's not fair for him to have a mom that is going to be sick for the rest of her life. It might not be bad today, but we don't know about tomorrow, you know? And I just, I feel guilt in that aspect of him just not having a healthy mom. Same for my husband, for him to have a wife that just isn't healthy, and it breaks my heart for them, really. But I try to stay positive and take care of myself as much as I can. But it definitely does play a huge role on your mental health, for sure, day to day. Some days I can be like, you know what?

• 17:07Speaker 02

  I am a warrior, I got this, everything's great. And other days it's like, I am not okay, and I feel like I could just crawl under a rock and stay there.

• 17:18Speaker 01

  Rachel, like a lot of people living with IgA nephropathy, has become an advocate, encouraging others to get checked.

• 17:25Speaker 02

  All of my friends, because of this, I'm like, please, get your yearlies done, but also ask for that urine test. You know, if you see any sign of protein in your urine, just double-check it, why not?

• 17:38Speaker 01

  Exactly. Why not? Kidney health is not top of mind for most people, but it's worth talking to your doctor about. You can also go to Vertex's website, V R T X dot com, for more information on Vertex's commitment to IgA nephropathy and other serious kidney diseases.

• 18:00Speaker 01

  This is Targeting the Toughest Diseases, a podcast from Bloomberg Media Studios and Vertex Pharmaceuticals. If you like what you hear, subscribe and leave us a review. I'm Jordan Goss-Pore. Thanks for listening.